HDAC9 and B-cell non-Hodgkin lymphoma: We demonstrated that the expression of a crucial HDAC, HDAC7, for B lymphocyte biology is lost in pro-B-ALL patients and in the B-ALL and B-cell lymphoma cell lines, and that its re-expression has a potent anti-oncogenic effect.